Joint conditions – such as osteoarthritis and degenerative changes in the joints – compromise the quality of life of millions of people around the world, causing chronic pain, stiffness and limited mobility.
IBSA has always been committed to the development of innovative solutions for each stage of disease progression, from oral therapies to intra-articular infiltrations based on hyaluronic acid, which help restore joint function and improve the mobility and quality of life of patients.
Thanks to our partnership with Lunatus, it is now possible to ensure, in Saudi Arabia and the United Arab Emirates, the large-scale use of innovative solutions from the Flector and Sinogel lines.
The partnership with Lunatus is part of IBSA’s global expansion strategy, which today can offer its therapeutic solutions in over 90 countries. The management of distributors includes a synergistic collaboration between the departments Pharma Distributors, Business Development and Marketing, which operate in a coordinated manner, following the different phases of the process of selecting, managing and supporting new partners.
The expansion into the Middle East strengthens IBSA’s desire to put the Person at the centre of every activity, offering effective and easily accessible therapeutic solutions.
This path is an integral part of IBSA’s philosophy, which has always valued the overall well-being of people, combining scientific innovation, therapeutic accessibility and a distribution model focused on solid and lasting relationships.
18-03-2025
By